ONCBeiGeneRunning, no new patients
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 590 (final count)
- Started
- Oct 31, 2017
- Main results expected
- May 7, 2021
- Fully finished
- Oct 31, 2027
- Results posted
- Nov 7, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR)
Measured over: Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03336333 · record last updated 2026-03-09 · checked 2026-11-09 15:47 UTC